Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape
Pain Management · Opioid • Regulatory Approval • Jun 28, 2026
Assessment confidence: 91% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's approval of Sun Pharma's ANDA for Levorphanol Tartrate signifies a new entry into the pain management market, which could disrupt existing pricing structures and market shares. Competitors must be vigilant in adjusting their strategies to maintain their positions in this evolving landscape. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).
Strategic Assessment
Strategic consideration for competitors includes adjusting pricing strategies and assessing market entry timing for their own products. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In rare disease, 8 regulatory and 1 competitive items passed relevance filtering for Sun Pharma.
Competitive Pressure
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Sun Pharma to enter the market with a generic version of Levorphanol Tartrate, potentially impacting pricing and market share for existing branded products.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — LEVORPHANOL TARTRATE (SUPPL) (FDA). Sub-indication match (rare disease); Entity match (levorphanol tartrate). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for other products.
Key Risks
- Potential for aggressive pricing strategies from Sun Pharma that could erode margins for existing branded products.
- Uncertainty regarding the timing and magnitude of competitive responses from other manufacturers.
- Regulatory risks associated with ongoing compliance and potential future changes in opioid regulations.
- Competitive pressure on Sun Pharma: This approval allows Sun Pharma to enter the market with a generic version of Levorphanol Tartrate, potentially impactin.
Key Opportunities
- The introduction of a generic version may lead to price reductions and increased competition, potentially affecting revenue streams for existing branded products in the opioid category.
- Strategic consideration for competitors includes adjusting pricing strategies and assessing market entry timing for their own products.
What Would Change This Assessment
- This becomes more urgent if Monitor the launch date and market uptake of Sun Pharma's Levorphanol Tartrate, as well as any competitive responses from other manufacturers.
- Timeline shift beyond near term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEvaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceLiposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceInvestigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceHuman Experimental Models of Pain (HEMP)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceComparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFactors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTwo-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
- FDA Grants AP Status for Levorphanol Tartrate ANDA213906 by Sun Pharma
Regulatory Approval
Related Regulatory Precedents
FDA
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
Application ANDA218417. Sponsor: AUROBINDO PHARMA LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DEXTROMETHORPHAN POLISTIREX.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075499. Sponsor: APOTEX. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075824. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA211484. Sponsor: ACERTIS PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA074278. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
Source